OTCPK:DMSI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Dermisonics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DMSI has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

DMSI

-1.7%

US Medical Equipment

-0.8%

US Market


1 Year Return

n/a

DMSI

16.5%

US Medical Equipment

13.8%

US Market

Return vs Industry: Insufficient data to determine how DMSI performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how DMSI performed against the US Market.


Shareholder returns

DMSIIndustryMarket
7 Day0%-1.7%-0.8%
30 Day0%-3.5%-5.7%
90 Day0%12.2%8.6%
1 Yearn/a17.5%16.5%16.4%13.8%
3 Year-100.0%-100.0%70.0%65.6%36.9%27.8%
5 Year-99.9%-99.9%139.5%121.3%85.0%64.2%

Price Volatility Vs. Market

How volatile is Dermisonics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dermisonics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Dermisonics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Dermisonics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Dermisonics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Dermisonics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Dermisonics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dermisonics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Dermisonics performed over the past 5 years?

15.4%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Dermisonics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • Examine Dermisonics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Dermisonics's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is Dermisonics's financial position?


In this section we usually analyse Dermisonics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Dermisonics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of DMSI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Dermisonics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Dermisonics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DMSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DMSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DMSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DMSI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DMSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.8yrs

Average board tenure


CEO

Bruce Haglund (68 yo)

no data

Tenure

Mr. Bruce H. Haglund, Esq., J.D., has been Executive Chairman of Dermisonics, Inc., since August 6, 2004 and serves as its Chief Executive Officer, Acting Principal Financial Officer and Acting Principal A ...


Board Members

NamePositionTenureCompensationOwnership
Bruce Haglund
Executive Chairmanno datano datano data
Bruce Redding
Director14.17yrsUS$154.17kno data
Theodore van de Kamp
Member of Advisory Board14.75yrsno datano data
Adil Saleh
Member of Business Advisory Councilno datano datano data

14.8yrs

Average Tenure

Experienced Board: DMSI's board of directors are seasoned and experienced ( 14.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Dermisonics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dermisonics, Inc.
  • Ticker: DMSI
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$63.000
  • Shares outstanding: 63.91m

Location

  • Dermisonics, Inc.
  • 2 Park Plaza
  • Suite 450
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DMSIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 2002

Biography

Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, call ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 05:26
End of Day Share Price2020/08/17 00:00
Earnings2007/06/30
Annual Earnings2006/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.